Home > Healthcare > Medical Devices > Diagnostic Devices > Ovarian Cancer Diagnostic Market

Ovarian Cancer Diagnostic Market Size

Report ID: GMI8316
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Ovarian Cancer Diagnostic Market Size

Ovarian Cancer Diagnostic Market size was valued at around USD 1.54 billion in 2023 and is anticipated to register a CAGR of 6.6% between 2024 and 2032. Ovarian cancer diagnostic refers to the process of identifying and determining the presence of ovarian cancer in individuals suspected of having the disease. Ovarian cancer diagnostic procedures encompass a range of tests, examinations, and imaging techniques aimed at detecting the presence of cancerous cells or tumors in the ovaries or surrounding tissues.

Ovarian Cancer Diagnostic Market

To get key market trends

Download Free Sample

The increasing incidence and prevalence of ovarian cancer worldwide have heightened the demand for effective diagnostic methods. For instance, in 2024, the American Cancer Society projects that approximately 19,680 new cases of ovarian cancer will be diagnosed among women in the U.S., while roughly 12,740 women are expected to succumb to the disease.

Ovarian Cancer Diagnostic Market Report Attributes
Report Attribute	Details
Base Year:	2023
Ovarian Cancer Diagnostic Market Size in 2023:	USD 1.54 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	6.6%
2032 Value Projection:	USD 2.71 Billion
Historical Data for:	2018 – 2023
No. of Pages:	250
Tables, Charts & Figures:	408
Segments covered:	Product Type, Diagnostic Tests, Cancer Type, End-use, and Region
Growth Drivers:	Rising incidence and prevalence of ovarian cancer Growing awareness and screening programs Increasing research and development activities Technological advancements in ovarian cancer diagnostics
Pitfalls & Challenges:	High treatment costs Stringent regulatory scenario

Learn more about the key segments shaping this market

Download Free Sample

Furthermore, ongoing research and development efforts in the field of oncology which is estimated to reach USD 690 billion by 2032, including ovarian cancer have led to the discovery of novel biomarkers, imaging techniques, and diagnostic technologies. This continuous innovation enhances the accuracy, sensitivity, and specificity of cancer diagnostics, enabling earlier detection of ovarian cancer and better patient outcomes.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global ovarian cancer diagnostic industry was valued at around USD 1.54 billion in 2023 and is estimated to reach over USD 2.71 billion by 2032, driven by increasing incidences of ovarian cancer worldwide.

Instruments/analyzers segment garnered USD 965.7 million in 2023 and is set to gain traction by 2032, driven by technological advancements and growing awareness about the importance of early detection and screening for ovarian cancer.

North America ovarian cancer diagnostic industry accounted for USD 624.4 million in 2023 and is predicted to witness substantial growth through 2032, driven by an advanced healthcare infrastructure and high levels of awareness regarding the importance of early cancer detection.

Abbott Laboratories, Agilent Technologies, Canon Medical Systems Corporation, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, GE HealthCare Technologies Inc., Illumina Inc., Myriad Genetics, Philips Healthcare, Positron Corporation are some of the major industry contenders.